|MDACC Study No:||2008-0288 (clinicaltrials.gov NCT No: NCT00882102)|
|Title:||Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|
|Principal Investigator:||Gautam Borthakur|
|Treatment Agent:||Decitabine; Gemtuzamab Ozogamicin|
|Study Description:||The goal of this clinical research study is to learn if 5-aza-2 deoxycytidine |
(decitabine) given in combination with Mylotarg (gemtuzumab ozogamicin) can
help to control AML, high-risk MDS or MF. The safety of this drug combination
will also be studied.